A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease

Masato Muraki1*, Yuki Kunita1, Ken Shirahase1, Ryo Yamazaki1, Soichiro Hanada1, Hirochiyo Sawaguchi1 and Yuji Tohda2

Abstract

Background: In chronic obstructive pulmonary disease (COPD) patients, combination treatment with long-acting muscarinic antagonist (LAMA) and long-acting β2 agonist (LABA) increases forced expiratory volume in one second and reduces symptoms compared to monotherapy. In Japan, three different once-daily fixed-dose combinations (FDCs) have been prescribed since 2015, although a direct comparison of these FDCs has never been performed. The objective of the present study was to compare the effectiveness, preference, and safety of three LAMA/LABA FDCs—glycopyrronium/indacaterol (Gly/Ind), umeclidinium/vilanterol (Ume/Vil), and tiotropium/olodaterol (Tio/Olo)—in patients with COPD.

Methods: We enrolled 75 COPD outpatients (male:female ratio, 69:6; 77.4 ± 6.9 years). A prospective, randomized, crossover study was conducted on three groups using three FDCs: Gly/Ind; Ume/Vil; and Tio/Olo. Each medication was administered for 4 weeks before crossover (total 12 weeks). After each FDC administration, a respiratory function test and questionnaire survey were conducted. A comparative questionnaire survey of all three LAMA/LABA FDCs was conducted after 12 weeks (following administration of final FDC).

Results: No significant differences in COPD Assessment Test or modified Medical Research Council dyspnea questionnaire were reported in the surveys completed after each FDC administration; no significant differences in spirometric items were observed. In the final comparative questionnaire survey, patients reported better actual feeling of being able to inhale following Gly/Ind administration compared with Tio/Olo, although no significant differences in adverse events or other evaluations were reported.

Conclusions: The three LAMA/LABA FDCs administered to COPD patients show similar effects and safety, although some minor individual preference was reported.

Trial registration This study retrospectively registered with the University Hospital Medical Information Network Clinical Trials Registry (number UMIN000041342, registered on August 6, 2020).

Keywords: Glycopyrronium/indacaterol, Umeclidinium/vilanterol, Tiotropium/olodaterol, Quality of life, Inhaler device, COPD
Background
An inhaled bronchodilator is a drug that increases forced expiratory volume in one second (FEV1), and/or improves other spirometric variables. Inhaled bronchodilators are central pharmacological treatments for chronic obstructive pulmonary disease (COPD). In particular, long-acting muscarinic antagonists (LAMAs) and β2 agonists (LABAs) significantly improve respiratory function, dyspnea, and health status, and significantly reduce exacerbation rates [1]. Compared to LAMA or LABA monotherapy, or an Inhaled corticosteroid (ICS)/LABA combination, LAMA/LABA co-treatment is superior in several aspects, including in the improvement of symptoms [2–4] and respiratory functions [3–5], and in the prevention of exacerbations [6–8]. Therefore, LAMA and LABA co-treatment is recommended when the effect of a single bronchodilator is inadequate [1]. LAMA/LABA combination therapy using a single inhaler is recommended to enhance adherence, to reduce medical costs [5, 9, 10], and to optimize the synergistic effect of LAMA and LABA [11, 12].

As of September 2019, four LAMA/LABA fixed-dose combination (FDC) medicines—glycopyrronium/indacaterol (Bevespi®), glycopyrronium/indacaterol (Gly/Ind; Ultibro®), umeclidinium/vilanterol (Ume/Vil; Anoro®), and tiotropium/olodaterol (Tio/Olo; Spiorto®)—are available for patients with COPD in Japan. Only Gly/Ind, Ume/Vil, and Tio/Olo are administered once daily. Although an indirect comparison of these three medications has previously been reported [13], direct comparisons between any two of these medications are limited [14, 15], and no direct controlled study of three once-daily FDC medications has been reported. Therefore, a direct controlled comparison study with Gly/Ind, Ume/Vil, and Tio/Olo was conducted, and the effectiveness, preference, and safety of these three medications were compared and investigated.

Methods
Patients
COPD outpatients aged 40 years old or over who attended the Department of Respiratory Medicine and Allergology at Kindai University Nara Hospital (Ikoma, Japan) between April 2017 and October 2019, and who were diagnosed as requiring LAMA and LABA, were included in this study. Prior informed consent was obtained from all patients. The exclusion criteria were as follows: inability to inhale unassisted; inability to perform spirometry tests; pregnancy; severe comorbidities affecting quality of life, including malignancy, cardiac failure, renal failure, or severe liver dysfunction; and comorbidity of severe prostatic hypertrophy and closed-angle glaucoma. Patients with overlapping asthma could be enrolled, if the asthma presented as a stable disease without any exacerbations during the six months prior to the study.

Study design
The open-labeled, prospective, randomized, crossover protocol used in this study is shown in Fig. 1. Subjects were randomly assigned to a Gly/Ind first group (Gly/Ind to Ume/Vil to Tio/Olo), an Ume/Vil first group (Ume/Vil to Tio/Olo to Gly/Ind), or a Tio/Olo first group (Tio/Olo to Gly/Ind to Ume/Vil) by the envelope method. Additional concomitant medications remained unchanged during the study. If ICS was used in an ICS/LABA combination, the dose of ICS monotherapy was adjusted to match the dose used in prior combination therapy. This study adheres to CONSORT guidelines.

Interventions
The background details of included patients were examined and recorded. A pharmacist instructed patients within each group to inhale the prescribed medication once daily for 4 weeks. After 4 weeks (for each treatment regimen), the following items were evaluated: a COPD Assessment Test (CAT); a modified Medical Research Council dyspnea questionnaire (mMRC); an original questionnaire concerning side effects, effects, and the device (Additional file 1: Table S1); spirometry, using a Chestac-33 (Chest M.I., Tokyo, Japan); and, respiratory system resistance and reactance, determined via the forced oscillation technique (FOT) using a MostGraph-01VR (Chest M.I., Tokyo, Japan). If exacerbation due to common cold or other causes overlapped with the visit date, the evaluation appointment could be postponed for up to 4 weeks. The examinations were performed from 9:30 am to 11 am, 2.5–3.5 h after the patients took their normal morning medications (the LAMA/LABA combination and all other morning medications). Upon completing the final course (after 12 weeks), an original questionnaire survey with a ranking policy (Additional file 1: Figure S1) was conducted to compare the three medications. The relationship between first-rank medication selected and patient background factors was subsequently investigated.

Statistical analyses
Data are presented as mean ± standard deviation. Statistical differences were assessed using analysis of variance (ANOVA: Tukey’s honestly significant difference test) to perform a comparison on all three groups. For analyzing the relationship between medication selected as first rank and background factor (continuous scale), ANOVA was performed to examine the difference among the three groups; Tukey’s honestly significant difference test was
used to estimate the difference between each group. For analyzing the relationship between medication selected as first rank and background factor (nominal scale), a χ² test was performed using a contingency table. Statistical analyses were performed using JMP® version 14.2.0 statistical software (SAS Institute Japan, Tokyo, Japan). A difference with a P value (P) < 0.05 was considered statistically significant.

Results
Seventy-five subjects were initially enrolled. The clinical characteristics of these patients are shown in Table 1. The population was 92% male, and included four current smokers. The mean percentage post-bronchodilator forced expiratory volume in one second (% post-BD FEV1) was 58.8%. Details of prior treatments are shown in Additional file 1: Table S2. As a prior therapeutic drug, LAMAs were used in 61 cases (81.3%); Tio was the most prescribed, and was used in 31 cases (50.8%). As a prior therapeutic drug, LABAs were used in 63 cases (84.0%); Ind was the most prescribed, and was used in 38 cases (60.3%). In addition, ICS were used in 25.3% cases; Ciclesonide was the most prescribed (52.6% of cases).

Table 1 Baseline clinical characteristics of patients

|                  | Enrolled (n=75) | Randomized |
|------------------|-----------------|------------|
| Gly/Ind (n=25)   |                 |            |
| Ume/Vil (n=25)   |                 |            |
| Tio/Olo (n=25)   |                 |            |
| 4 weeks          |                 | Examination, questionnaire |
| Gly/Ind          |                 | Examination, questionnaire |
| Tio/Olo          |                 | Examination, questionnaire |
| Ume/Vil          |                 | Examination, questionnaire |
| 4 weeks          |                 | Examination, questionnaire |
| Gly/Ind          |                 | Examination, questionnaire |
| Tio/Olo          |                 | Examination, questionnaire |
| 4 weeks          |                 | Examination, questionnaire |
| Gly/Ind          |                 | Examination, questionnaire |
| Ume/Vil          |                 | Examination, questionnaire |
| Final comparative questionnaire survey (n=71) |

Fig. 1 Trial profile

| Baseline clinical characteristic | n | IC (L) | BMI (kg/m²) | PIF (L/min) | Adaptor-free | H/H | Asthma |
|---------------------------------|---|--------|-------------|-------------|--------------|-----|--------|
| N                               | 75 | 1.91 ± 0.51 | 22.0 ± 3.0 | 195.1 ± 62.3 | 4.24 ± 7.4 | 8   |        |
| Male/female                     | 69.6 | 2.81 ± 0.72 | 164.0 ± 7.2 | 42.4 ± 7.4 | 1.22 ± 0.94 | 4   |        |
| Age (years)                     | 77.4 ± 6.9 (53–91) | 1.42 ± 0.54 | 59.3 ± 9.8 | 22.0 ± 3.0 | 1.46 ± 0.54 | 4.24 ± 7.4 | 8 |
| Height (cm)                     | 164.0 ± 7.2 | FEV1/FVC (%) | 50.5 ± 13.5 | 42.4 ± 7.4 | 1.46 ± 0.54 | 1.22 ± 0.94 | 8 |
| Body weight (kg)                | 59.3 ± 9.8 | MMF (L/s) | 0.56 ± 0.35 | 22.0 ± 3.0 | 1.22 ± 0.94 | 4.24 ± 7.4 | 8 |
| BMI (kg/m²)                     | 22.0 ± 3.0 | PF (L/s) | 4.37 ± 1.72 | 164.0 ± 7.2 | 1.46 ± 0.54 | 42.4 ± 7.4 | 8 |
| Smoking (pack year)             | Former: 71 | V50 (L/s) | 0.71 ± 0.47 | 22.0 ± 3.0 | 1.46 ± 0.54 | 42.4 ± 7.4 | 8 |
| Current: 4                      | V25 (L/s) | 0.25 ± 0.14 | 5.26 ± 2.68 | 22.0 ± 3.0 | 1.46 ± 0.54 | 42.4 ± 7.4 | 8 |
| 52.6 ± 26.8                     | V50/V25 | 2.87 ± 1.06 | 52.6 ± 26.8 | 22.0 ± 3.0 | 1.46 ± 0.54 | 42.4 ± 7.4 | 8 |

BMI, body mass index; PIF, peak inspiratory flow; H/H, adaptor for handihaler; IC, inspiratory capacity; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; MMF, maximal mid-expiratory flow; PF, peak expiratory flow; V50, forced expiratory flow at 50% of FVC; V25, forced expiratory flow at 25% of FVC; BD, bronchodilator.
Prior to the study, LAMA/LABA FDCs were used in 27 cases (Gly/Ind, 19 cases; Ume/Vil, four cases; Tio/Olo, four cases).

The trial profile is shown in Fig. 1. Enrolled subjects were randomly divided into three groups: Gly/Ind first group; Ume/Vil first group, or Tio/Olo first group. Four cases were not included in the final analysis of our study: two cases dropped out due to the influences of other diseases; one case dropped out with exacerbation; four cases were not included in the final analysis of our study: two cases dropped out due to the influences of other diseases; one case dropped out with exacerbation; and one case did not complete the return visit to the hospital. Therefore, in total, 71 cases were analyzed. All subjects analyzed were investigated at 4 weeks without any postponement.

According to the questionnaire surveys completed at the end of each medication, no significant difference in CAT score or mMRC score was reported between each group (Table 2). In total, 11 adverse events were recorded during the trial. Therefore, in total, 71 cases were analyzed. All subjects analyzed were investigated at 4 weeks without any postponement.

The rankings for “Shape, size, or design” evaluation for Gly/Ind performed significantly better than Ume/Vil and Tio/Olo. For the item “Actual feeling of being able to inhale”, Gly/Ind performed significantly better than Ume/Vil and Tio/Olo. In addition, Gly/Ind performed significantly better than Ume/Vil in the item “Overall evaluation” (Table 2).

The results of the respiratory function test are reported in Table 3. For spirometry and FOT, there were no significant differences in all items. In the expiratory phase, inspiratory phase, and expiratory phase minus inspiratory phase, there were also no significant differences for all FOT items (Additional file 1: Table S3).

In the end of study comparative questionnaire, the ranking of “Actual feeling of being able to inhale” was significantly better for Gly/Ind compared with Tio/Olo; Gly/Ind also tended to be better than Ume/Vil.

### Table 2: Scores on CAT, mMRC, and original questionnaire survey, and visual analog scale after using each inhaler

|                     | Gly/Ind | Ume/Vil | Tio/Olo | Gly/Ind versus Ume/Vil | Gly/Ind versus Tio/Olo | Ume/Vil versus Tio/Olo |
|---------------------|---------|---------|---------|------------------------|------------------------|------------------------|
| CAT                 | 14.2±8.5| 14.6±9.0| 14.1±8.6| 0.9454                 | 0.9975                 | 0.9208                 |
| mMRC                | 1.86±0.95| 1.80±1.01| 1.89±0.95| 0.9359                 | 0.9836                 | 0.8617                 |
| **Original questionnaire** |         |         |         |                        |                        |                        |
| ① Hoarseness        | 0.39±0.84| 0.31±0.67| 0.28±0.54| 0.7473                 | 0.5964                 | 0.9681                 |
| ② Discomfort or irritation of the throat | 0.39±0.62| 0.51±0.91| 0.27±0.51| 0.6027                 | 0.5273                 | 0.1051                 |
| ③ Cough immediately after inhalation | 0.54±0.69| 0.56±0.86| 0.46±0.75| 0.9742                 | 0.8495                 | 0.7267                 |
| ④ Aftertaste        | 0.31±0.60| 0.65±0.83| 0.23±0.45| 0.0059                 | 0.7164                 | 0.0004                 |
| ⑤ Headache          | 0.10±0.45| 0.08±0.41| 0.10±0.34| 0.9764                 | 1                      | 0.9764                 |
| ⑥ Palpitation       | 0.14±0.35| 0.20±0.52| 0.08±0.33| 0.692                  | 0.692                  | 0.2325                 |
| ⑦ Tremor            | 0.06±0.23| 0.10±0.34| 0.08±0.28| 0.6597                 | 0.8309                 | 0.0547                 |
| ⑧ Eye pain, bleariness | 0.20±0.52| 0.34±0.70| 0.32±0.63| 0.3671                 | 0.4436                 | 0.9899                 |
| ⑨ Thirst            | 0.59±0.87| 0.53±0.84| 0.46±0.71| 0.8633                 | 0.622                  | 0.9102                 |
| ⑩ Constipation      | 0.32±0.63| 0.46±0.77| 0.30±0.62| 0.4303                 | 0.9666                 | 0.2981                 |
| ⑪ Difficulty of urination | 0.30±0.54| 0.31±0.71| 0.28±0.68| 0.9908                 | 0.9908                 | 0.9638                 |
| ⑫ About shape, size or design | 1.01±0.62| 1.42±0.77| 1.21±0.75| 0.0024                 | 0.2323                 | 0.1878                 |
| ⑬ About inhaler operation and procedure | 1.06±0.63| 1.23±0.74| 1.14±0.68| 0.3082                 | 0.7435                 | 0.7435                 |
| ⑭ About actual feeling of being able to inhale | 1.01±0.73| 1.45±1.01| 1.64±0.90| 0.0103                 | <0.0001                | 0.3821                 |
| ⑮ About actual effect | 1.58±0.80| 1.80±0.77| 1.70±0.74| 0.1936                 | 0.5919                 | 0.7277                 |
| ⑯ Overall evaluation | 1.35±0.79| 1.70±0.93| 1.54±0.73| 0.0311                 | 0.3836                 | 0.4416                 |
| Visual Analog Scale (cm) | 6.65±2.21| 6.09±2.32| 6.06±2.10| 0.2924                 | 0.2514                 | 0.9954                 |

CAT, COPD Assessment Test; mMRC, modified Medical Research Council dyspnea questionnaire
Table 3 Spirometry and FOT by MostGraph-01® after using each inhaler

|        | Gly/Ind | Ume/Vil | Tio/Olo | P value |
|--------|---------|---------|---------|---------|
|        | Gly/Ind versus Ume/Vil | Gly/Ind versus Tio/Olo | Ume/Vil versus Tio/Olo |
| Spirometry |         |         |         |         |
| IC (L)  | 2.02±0.54 | 2.03±0.57 | 2.04±0.56 | 0.9939 | 0.9544 | 0.9812 |
| FVC (L) | 2.87±0.74 | 2.88±0.72 | 2.95±0.75 | 0.9993 | 0.8137 | 0.8332 |
| FEV1 (L)| 1.52±0.57 | 1.51±0.56 | 1.52±0.56 | 0.9969 | 0.9999 | 0.9977 |
| MMF (L/s)| 0.64±0.38 | 0.62±0.36 | 0.61±0.38 | 0.9620 | 0.8849 | 0.9769 |
| PF (L/s)| 4.77±1.92 | 4.73±1.78 | 4.76±1.83 | 0.9891 | 0.9991 | 0.9944 |
| V50 (L/s)| 0.83±0.52 | 0.82±0.53 | 0.80±0.56 | 0.9008 | 0.9457 | 0.9805 |
| V25 (L/s)| 0.29±0.15 | 0.27±0.13 | 0.26±0.15 | 0.6932 | 0.6318 | 0.9947 |
| V50/V25| 2.90±1.11 | 2.97±1.18 | 2.97±1.22 | 0.9279 | 0.9187 | 0.9997 |
| FOT (average) |         |         |         |         |
| RS (cmH2O/L/s) | 3.35±1.11 | 3.38±1.11 | 3.30±1.19 | 0.9856 | 0.9568 | 0.8966 |
| R20 (cmH2O/L/s) | 2.58±0.85 | 2.65±0.85 | 2.52±0.81 | 0.8771 | 0.9049 | 0.6321 |
| RS–R20 (cmH2O/L/s) | 0.78±0.42 | 0.74±0.40 | 0.78±0.50 | 0.8418 | 0.9997 | 0.8288 |
| V5 (cmH2O/L/s) | 1.25±1.12 | 1.25±1.12 | 1.32±1.31 | 0.9997 | 0.9413 | 0.9335 |
| V25 (cmH2O/L/s) | 12.75±4.88 | 12.67±4.88 | 12.85±5.28 | 0.9952 | 0.9923 | 0.9754 |
| ALX (cmH2O/L) | 8.50±10.18 | 8.44±9.78 | 9.39±12.39 | 0.9993 | 0.8781 | 0.8611 |

FOT, forced oscillation technique; IC, inspiratory capacity; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; MMF, maximal mid-expiratory flow; PF, peak expiratory flow; V50, forced expiratory flow at 50% of FVC; V25, forced expiratory flow at 25% of FVC; RS, resistance of respiratory system at 5 Hz; R20, resistance of respiratory system at 20 Hz; X5, reactance of respiratory system at 5 Hz; Fres, resonant frequency; ALX, low-frequency reactance area

Vil, although there was no significant difference ($P = 0.0618$). No significant differences were reported in the ranking of all other questionnaire items (Fig. 2). Regarding the reasons provided for selection preference (Additional file 1: Table S4), 57 subjects responded to free comments (14 did not respond). The reasons provided for selecting Gly/Ind included “a good feeling of being able to inhale due to transparent capsule or sound during inhalation” in 16 subjects and “good effects” in seven subjects. Ten subjects preferred Ume/Vil because of its easy operability. Reasons provided for preferring Tio/Olo included “Good effects” (four subjects) and the “Actual feeling of inhalation” (four subjects). One subject evaluated all three agents as equivalent.

Finally, the relationship between the medication selected as the first rank in the final comparative questionnaire and the background factors of the patients (sex, age, height, weight, BMI, PIF, respiratory function, presence or absence of asthma complication, types of inhalation device at baseline, presence or absence of ICS use, and order of LAMA/LABA FDCs) were investigated (Additional file 1: Table S5). However, no significant difference in the relationship between the first-ranking LAMA/LABA FDC and all background factors was observed.

**Discussion**

Although the comparative efficiency and safety of different LAMA/LABA FDCs were previously reported in an indirect study (Tio/Olo $\gg$ Ume/Vil $\gg$ Gly/Ind) [13], published findings concerning a direct comparison of Tio/Olo, Ume/Vil, and Gly/Ind are limited. These three LAMA/LABA FDCs were previously found to have similar incremental cost-effectiveness ratios [16], efficacy, and safety [17]. In a comparison of two medications, Ume/Vil was reported to be superior to Tio/Olo in rescue medication use and medication adherence [18], and was also reported to show better cost-effectiveness (compared to Tio/Olo) [19]. In a direct comparison test, Ume/Vil was superior to Tio/Olo regarding the change of trough FEV1 [14, 15]. However, taken together, the published reports appear to be contradictory. Moreover, the previous reports are limited direct comparison studies between two medications, retrospective studies, or indirect studies of the three medications. Therefore, to conclusively determine LAMA/LABA FDC efficacy, safety, and preference, we decided to conduct a direct comparison study of all three medications. This is the first prospective direct comparative study (open-labeled) among three once-daily LAMA/LABA FDCs.

The peak inspiratory flow (PIF) value is an important manifestation of the effects of inhaled drugs [5]. In this
study, a Handihaler® adapter, a device with high intrinsic airflow resistance [20, 21], was used to measure PIF (the PIF meter adapter for Ellipta® had not been released at the start of this study). From the PIF levels, we determined that Ellipta® can be inhaled by most patients. No significant difference in respiratory functions was reported in this study, and no significant difference was also observed in CAT, mMRC, or in the actual effect (as reported in questionnaire surveys after each inhaler use and at the end of the study).

Although Gly/Ind was rated the best on “Actual feeling of being able to inhale” and superior to Ume/Vil on shape and overall evaluation in the survey after using each inhaler, Gly/Ind seemed to be preferred only on “Actual feeling of being able to inhale” in the final comparison survey (at the end of study). Although the reason for this preference was unknown, the transparent inhalation capsule or the sound produced during inhalation, may explain the inhalation feeling reported in the free comments.

In the final comparison survey, Ume/Ind was ranked first more times than the other medications for inhaler operation and procedure. However, no significant difference was reported among the three medications. In the free comments, ten subjects reported ease of operability as the reason for their stated preference. It should be noted that Ellipta has a higher correct use rate and a lower error rate than MDI [22].

Respimat® demonstrated the lowest amount of particles deposited in a mouth-throat model, and the highest amount of particles reaching all regions of the simulation lung model (compared to Breezhaler® and Ellipta®) [23]. Unsurprisingly, feelings of discomfort or irritation in the throat reported in the survey after 4 weeks treatment with each medication were lowest for Tio/Olo, although there were no significant differences.

Regarding the safety of each medication [4, 24–26], the scores of side effects reported in the questionnaire survey were less than one after each medication; there were no significant differences except for “Aftertaste”. There were also no withdrawals due to adverse events. Therefore, it was concluded that the tolerability of each medication was good. According to recent reports, LAMA/LABA combination therapy may improve left ventricular end-diastolic volume, possibly by improving lung hyperinflation [27]. Moreover, LAMA/LABA combination therapy may improve cardiac function in COPD patients with heart failure [28].

Fig. 2 End of study Questionnaire. Selection and ranking of medications by patients. a Shape, size, or design; b Inhaler operation and procedure; c Actual feeling of being able to inhale; d Actual effect; e Side effects; f Overall evaluation; g Selection (“Which would you like to use from now on?”)
As important limitations of this study, there is the fact that issues regarding inhaler device handling were not accounted for. Although inhaler device handling is undoubtedly important [29], we could not confirm whether or not inhalation was always successful. Nonetheless, demonstration is the most effective means for device operation instruction [30], and handling instructions were provided through both demonstrations and written instructions. Secondly, washing out periods could not be provided due to the real world clinical setting. Thirdly, the number of patients who used Gly/Ind before this study was higher than that of Ume/Vil or Tio/Olo users (19 subjects vs. 4 subjects in other FDCs). This difference might have influenced the preferences such as “Actual feeling of being able to inhale”. Finally, compared to global reports, the proportion of women with COPD in Japanese COPD studies is small (8.0–14.5%) [31–33]; the proportion of women in this study was also small (8.0%). These differences in sex ratios between various countries might have influenced results such as preference.

Conclusions
Except for the “Actual feeling of being able to inhale”, there was no definitive clinical difference among the three LAMA/LABA FDCs. Moreover, the safety profiles of all three LAMA/LABA FDCs were very good. Although the characteristics of patients who expressed a preference for one of the three medications were investigated, characteristic factors that predicted which medications was preferred could not be found.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12890-021-01403-y.

Additional file 1: Figure S1. End of the study comparative questionnaire concerning all three medications. Table S1. Original questionnaire for completion after using each inhaler. Table S2. Treatments used prior to this study. Table S3. Forced oscillation technique (FOT) at expiration phase, inspiration phase, and Δexpiration minus inspiration phase using MostGraph® after each inhaler use. Table S4. Reasons for selection (in free comments). Table S5. Relationship between first-ranking LAMA/LABA FDC and background factors of patients.

Abbreviations
ANOVA: Analysis of variance; CAT: COPD Assessment Test; COPD: Chronic obstructive pulmonary disease; FOC: Fixed-dose combination; FEV1: Forced expiratory volume in one second; Gly: Glycopyrronium; ICS: Inhaled corticosteroid; Ind: Indacaterol; LABA: Long-acting β2 agonist; LAMA: Long-acting muscarinic antagonist; mMRC: Modified Medical Research Council dyspnea questionnaire; Olo: Olodaterol; PIF: Peak inspiratory flow; Tio: Tiotropium; Ume: Umeclidinium; Vil: Vilanterol.

Acknowledgements
We would like to thank Editage (www.editage.com) for English language editing.

Authors' contributions
MM directed the execution of the study, participated in the assaying of the samples, conducted statistical analyses and interpretations, and wrote the manuscript; YK, KS, RS, SH, and HS enrolled subjects and contributed to data collection; YT was involved in study design and final approval of the version to be published. All authors have read and approved the manuscript.

Funding
No funding was obtained for this study.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent participate
The study protocol (IRB #398, Jan. 2017) was approved by the Institutional Review Board at Kindai University Nara Hospital, and written informed consent was acquired from all subjects prior to enrollment into the study.

Consent for publication
Not applicable.

Competing interests
Yuji Tohda received research grant from Kyorin pharmaceutical, MeijiSeika pharma, Boeillringer Ingelheim, Teijin pharma, DaiichiSankyo, Astellas, and Pearl Therapeutics Inc. and received lecture fees from Kyorin pharmaceutical and Teijin Pharma, outside of the submitted work. Other authors have no competing interests to declare.

Author details
1 Department of Respiratory Medicine and Allergology, Kindai University Nara Hospital, 1248-1 Otoda-cho, Ikoma, Nara 630-0293, Japan. 2 Department of Respiratory Medicine and Allergology, Kindai University Hospital, 377-2 Ohnohigashi, Osaka, Osaka 589-8511, Japan.

Received: 8 September 2020 Accepted: 5 January 2021

Published online: 13 January 2021

References
1. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for diagnosis, management, and prevention of chronic obstructive lung disease (2020 Report). https://goldcopd.org/gold-reports. Accessed 15 Aug 2020.
2. Strange C, Walker V, DePietro M, Tong J, Kurlander J, Carlyle M, et al. Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:1377–88.
3. Donohue JF, Jones PW, Bartels C, Marvel J, D’Andrea P, Banerji D, et al. Correlations between FEV1 and patient-reported outcomes: a pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2018;49:11–9.
4. Rogliani P, Calzetta L, Braido F, Cazzola M, Clini E, Pelaia G, et al. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:3115–30.
5. Anzueto A, Miravitlles M. The role of fixed-dose dual bronchodilator therapy in treating COPD. Am J Med. 2018;131:608–22.
6. Calverley PMA, Anzueto AR, Carter K, Grönke L, Hallmann C, Jenkins C, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6:337–44.
7. Beeh KM, Burgel PR, Franssen FME, Lopez-Campos JL, Loukides S, Hurst JR, et al. How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2017;196:139–49.
8. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222–34.
9. Casas A, Montes de Oca M, Menezes AM, Wehrmeister FC, Lopez-Varela MV, Mendoza L, et al. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study. Int J Chron Obstruct Pulmon Dis. 2018;13:1545–56.

10. Chan MC, Tan EC, Yang MC. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:1079–88.

11. Cazzola M, Calzetta L, Puxeddu E, ORA J, Facciolo F, Rogliani P, et al. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. Respir Res. 2016;17:70.

12. Calzetta L, Matera MG, Cazzola M. Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy. Curr Open Pharmacol. 2018;40:95–103.

13. Rogliani P, Matera MG, Ritondo BL, De Guido I, Puxeddu E, Cazzola M, et al. Efficacy and cardiorespiratory safety profile of dual bronchodilator therapy in chronic obstructive pulmonary disease: a bidimensional comparative analysis across fixed-dose combinations. Pulm Pharmacol Ther. 2019;59:101-841.

14. Feldman GJ, Sousa AR, Lipson DA, Toms B, Barnes N, Riley JH, et al. Comparative efficacy of once-daily umclidinium/vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized study. Adv Ther. 2017;34:2518–33.

15. Alcázar Navarrete B, Boucot I, Naya I, Toms B, Lipson DA, Compton C, et al. Umclidinium/vilanterol versus tiotropium/olodaterol in maintenance-naïve patients with moderate symptomatic chronic obstructive pulmonary disease: a post hoc analysis. Pulm Ther. 2018;4:171–83.

16. Tebbboth A, Ternouth A, Gonzalez-Rojas N. UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD. Clinicoecon Outcomes Res. 2016;8:667–74.

17. Schlueter M, Gonzalez-Rojas N, Baldwin M, Groenke L, Voss F, et al. Pharmacological efficacy and fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis. Ther Adv Respir Dis. 2016;10:89-104.

18. Moretz C, Bengtson LG, Sharpsten L, Koep E, Le L, Tong J, et al. Evaluation of rescue medication use and medication adherence receiving umclidinium/vilanterol versus tiotropium bromide/olodaterol. Int J Chron Obstruct Pulmon Dis. 2019;14:2047–60.

19. Driessen MT, Whalen J, Seewoodharry Buguth B, Vallejo-Aparicio LA, Naya IP, Asukai Y, et al. Cost-effectiveness analysis of umclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. Respir Res. 2018;19:224.

20. Altman P, Wehbe L, Dederichs J, Guerin T, Ament B, Moronta MC, et al. Comparison of peak inspiratory flow rate via the Brezhaler®, Ellipta® and Handihaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial. BMC Pulm Med. 2018;18:100.

21. D’Urzo A, Chapman KR, Donohue JF, Kardos P, Maleki-Yazdi MR, Price D. Inhaler devices for delivery of LABA/LAMA fixed-dose combinations in patients with COPD. Pulm Ther. 2019;5:23–41.

22. Kerwin EM, Preece A, Brintziki D, Collison KA, Sharma R. ELLIPTA dry powder versus metered-dose inhalers in an optimized clinical trial setting. J Allergy Clin Immunol Pract. 2019;7:1843–9.

23. Ciciliani AM, Languth P, Wachtel H. In vitro dose comparison of Respin™ inhaler with dry powder inhalers for COPD maintenance therapy. Int J Chron Obstruct Pulmon Dis. 2017;12:1565–77.

24. Dahl R, Chapman KR, Rudolf M, Mehta R, Kho P, Alagappan VK, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med. 2013;107:1558–67.

25. Maleki-Yazdi MR, Kaelin T, Richard N, Zvanch M, Church A. Efficacy and safety of umclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108:1752–60.

26. Miravitlles M, Urtuaga G, Mathioudakis AG, Ancochea J. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis. Respir Res. 2017;18:196.

27. Hohfeld JM, Vogel-Clausen J, Biller H, Berliner D, Berschneider K, Tillmann HC, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018;6:368–78.

28. Cosentino ER, Landollo M, Bentvenga C, Spinardi L, Espositi DD, Cicero AF, et al. Morbidity and mortality in a population of patients affected by heart failure and chronic obstructive pulmonary disease: an observational study. BMC Cardiovasc Disord. 2019;19:20.

29. Molimard M, Raherison C, Lignot S, Balestra A, Lamarque S, Chartier A, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017;49:1601794.

30. Price D, Keininger DL, Viswanad B, Gasser M, Walda S, Guttzwiller FS. Factors associated with appropriate inhaler use in patients with COPD—lessons from the REAL survey. Int J Chron Obstruct Pulmon Dis. 2018;13:695–702.

31. Ishii T, Nishimura M, Akimoto A, James MH, Jones P. Understanding low COPD exacerbation rates in Japan: a review and comparison with other countries. Int J Chron Obstruct Pulmon Dis. 2018;13:3493–71.

32. Yamada H, Hida N, Hizawa N. Effects of a single long-acting muscarinic antagonist agent and a long-acting beta2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan. Int J Chron Obstruct Pulmon Dis. 2018;13:3141–7.

33. Minakata Y, Motegi T, Ueki J, Gon Y, Nakamura S, Anzai T, et al. Effect of tiotropium/olodaterol on sedentary and active time in patients with COPD: post hoc analysis of the VESUTO study. Int J Chron Obstruct Pulmon Dis. 2019;14:1789–801.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.